Lead Product(s) : Utreloxastat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PTC Therapeutics Discontinues Development of ALS Drug After Trial Failure
Details : PTC857 (utreloxastat) is being evaluated in the mid-stage clinical trial studies for the treatment of amyotrophic lateral sclerosis.
Brand Name : PTC857
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 26, 2024
Lead Product(s) : Utreloxastat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Utreloxastat
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857
Details : The Phase 1 study will evaluate PTC857 in healthy human volunteers with single and multiple ascending doses that will inform safety and pharmacology, and the design for the Phase 2 program.
Brand Name : PTC857
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2020
Lead Product(s) : Utreloxastat
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?